主页
市场
图表与思路
Algo
新闻
商店
经纪商
下载
经济日历
交易信号
网页端
热图
键入
/
进行搜索:@user,$symbol
查找
登录
创建账户
中文
English
Русский
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
VKTX
#1461
Viking Therapeutics, Inc
35.5
0
USD
+0.14%
版块:
医疗保健
基础:
USD
利润货币:
USD
日范围
年范围
日变化
+0.14%
每月变动
-0.81%
6个月变化
+8.23%
年变化
+60.78%
前一天收盘价
35.4
5
开盘价
35.5
4
买价
卖价
最低价
35.2
6
High
35.6
6
交易量
509
市场
股票
医疗保健
VKTX
展开完整图表
Financials
概览
声明
统计
每季度
年度
利润表
资产负债表
现金流
值
Q4, 24
Q1, 25
Q2, 25
Q3, 25
Q4, 25
总资产
908.32 M
866.99 M
827.85 M
739.41 M
715.73 M
负债总额
28.04 M
20.07 M
32.39 M
26.39 M
76.67 M
权益总额
880.28 M
846.92 M
795.46 M
713.03 M
639.06 M
负债及股东权益总额
908.32 M
866.99 M
827.85 M
739.41 M
715.73 M
总债务
—
—
—
—
—
净债务
—
—
—
—
—
新闻
LLY Stock Down as FDA Asks for More Safety Data on Oral Obesity Pill
How Will Mounjaro and Zepbound Sales Aid LLY's Upcoming Q1 Results?
Viking Therapeutics, Inc. (VKTX) Exceeds Market Returns: Some Facts to Consider
Does NVO Face Rising Competitive Pressure on LLY's Foundayo Approval?
Is Viking Therapeutics (VKTX) a Buy as Wall Street Analysts Look Optimistic?
Viking Therapeutics, Inc. (VKTX) Surpasses Market Returns: Some Facts Worth Knowing
NVO Crashes 36% in 3 Months: Is This an Indication to Sell the Stock?
LLY Launches GLP-1 Pill, Expands Access Through Pharmacy Partnerships
3 Best Stocks Under $50 to Buy in April 2026, According to Analysts - TipRanks.com
Recursion Pharmaceuticals (RXRX) Down 16.5% Since Last Earnings Report: Can It Rebound?
WVE Posts Interim Data From Phase I Study on WVE-007, Stock Tanks
VKTX Finishes Enrollment in Second Late-Stage Study on Obesity Drug